Taysha Gene Therapies Debt to Equity Ratio 2020-2026 | TSHA
Current and historical debt to equity ratio values for Taysha Gene Therapies (TSHA) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Taysha Gene Therapies debt/equity for the three months ending March 31, 2026 was 0.20.
| Taysha Gene Therapies Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2026-03-31 | $0.09B | $0.21B | 0.42 |
| 2025-12-31 | $0.10B | $0.25B | 0.39 |
| 2025-09-30 | $0.10B | $0.22B | 0.45 |
| 2025-06-30 | $0.09B | $0.25B | 0.34 |
| 2025-03-31 | $0.08B | $0.06B | 1.51 |
| 2024-12-31 | $0.09B | $0.07B | 1.24 |
| 2024-09-30 | $0.09B | $0.09B | 1.03 |
| 2024-06-30 | $0.09B | $0.11B | 0.84 |
| 2024-03-31 | $0.10B | $0.05B | 1.84 |
| 2023-12-31 | $0.10B | $0.08B | 1.31 |
| 2023-09-30 | $0.25B | $-0.05B | -4.99 |
| 2023-06-30 | $0.12B | $-0.04B | -3.20 |
| 2023-03-31 | $0.12B | $-0.02B | -7.80 |
| 2022-12-31 | $0.13B | $0.00B | 132.06 |
| 2022-09-30 | $0.10B | $0.01B | 9.02 |
| 2022-06-30 | $0.11B | $0.03B | 3.35 |
| 2022-03-31 | $0.12B | $0.05B | 2.27 |
| 2021-12-31 | $0.12B | $0.10B | 1.24 |
| 2021-09-30 | $0.10B | $0.14B | 0.72 |
| 2021-06-30 | $0.06B | $0.19B | 0.30 |
| 2021-03-31 | $0.02B | $0.22B | 0.09 |
| 2020-12-31 | $0.01B | $0.25B | 0.03 |
| 2020-09-30 | $0.01B | $0.27B | 0.04 |
| 2020-06-30 | $0.00B | $0.00B | 0.00 |
| 2020-03-31 | $0.00B | $0.00B | 0.00 |
| 2019-12-31 | $0.00B | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.290B | $0.010B |
| Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |